8.4 Drug Administration & Therapy Management

8.4 Drug Administration & Therapy Management

Quick Answer: NABP competency 2.2 asks when pharmacists and non-pharmacist personnel may participate in administration and therapy management. In Illinois, start with 225 ILCS 85/3(d): administration is limited to defined pathways (patient education; vaccines; certain injectables), plus COVID-19 therapeutics (3(d)(16)) and point-of-care testing/screening/treatment for a listed set of conditions (3(d)(17)) using CLIA-waived tests or established statewide protocol screening. Techs/students may perform administrative/technical testing tasks under supervision and may administer certain vaccines under 9.6. Always document, notify the patient’s physician when required, and refer when results or clinical status demand it.

This section stitches together administration, MTM/protocol care, and test-and-treat without re-teaching the entire immunization chapter.

Competency Area 2.2 Decision Frame

On every administration/therapy-management stem, run this checklist:

1. What act is being performed (inject, educate, test, treat, modify therapy)?
2. Who is the actor (pharmacist, student pharmacist, registered tech, clerical)?
3. What authority exists (patient-specific Rx, standing order, hospital P&T, statutory ordering authority)?
4. What training is required?
5. What supervision is required if non-pharmacists participate?
6. What documentation, notification, and referral are required?
7. Does the answer invent diseases or ages not in statute? If yes → wrong.

Drug Administration Pathways in 3(d)(4)

The practice of pharmacy includes drug administration limited to oral, topical, injectable, and inhalation as follows:

(A) Patient education on proper use or delivery

Pharmacists may administer in the context of teaching proper use/delivery (e.g., technique demonstration frameworks contemplated by the statute). This is education-linked administration, not a blank “inject anything.”

(B) Vaccinations (age 7+)

Covered in Section 8.2: Rx or standing order, training, adverse-reaction competence, physician notification, records (or hospital P&T).

(C) Alpha-hydroxyprogesterone caproate injections

Administration pursuant to a valid prescription by a physician licensed in all its branches, after appropriate training (contraindications/adverse reactions per rule), with notification to the patient’s physician and record retention, or hospital P&T policies.

(D) Long-acting injectables for mental health or substance use disorders

Administration pursuant to a valid prescription by the patient’s physician, APRN, or physician assistant, after ACPE-accredited appropriate training (including contraindications/adverse reactions per rule), with notification and record retention, or hospital P&T policies.

Exam contrast: Vaccine standing-order pathways are broad public-health tools; LAI mental health/SUD language emphasizes a valid prescription from the patient’s authorized prescriber plus ACPE training—not casual walk-up injection without that framework.

COVID-19 Therapeutics: 3(d)(16)

Pharmacists may order and administer COVID-19 therapeutics subcutaneously, intramuscularly, or orally with notification to the patient’s physician and appropriate record retention, or pursuant to hospital P&T policies. Eligible therapeutics are FDA approved, authorized, or licensed and must be administered in accordance with that approval/authorization/licensing.

Techs/students: 9.6(b) allows administration of COVID-19 therapeutics under a parallel supervision/training/CPR/immediate-availability structure—still not unsupervised clinical freelancing.

Test-and-Treat / CLIA-Waived Testing: 3(d)(17)

Illinois expressly includes ordering and administration of point-of-care tests, screenings, and treatments for:

1. Influenza
2. SARS-CoV-2
3. Group A Streptococcus
4. Respiratory syncytial virus (RSV)
5. Adult-stage head louse
6. Health conditions identified by a statewide public health emergency (as defined in the Illinois Emergency Management Agency Act)

…with notification to the patient’s physician, if any, and appropriate record retention, or hospital P&T policies.

Eligible tests and clinical decision tools

• Eligible tests/screenings are those FDA approved, authorized, or licensed and used in accordance with that status
• A pharmacist who orders/administers tests or screenings for these conditions may use a test that may guide clinical decision-making for the health condition that is waived under CLIA (Clinical Laboratory Improvement Amendments of 1988) and regulations, or any established screening procedure established under a statewide protocol

Do not invent a free-form disease list (e.g., “any infection,” “all chronic diseases,” “cancer screening panels”) beyond the statute. Emergency-declared conditions expand only when the statewide public health emergency mechanism applies.

Delegation of technical testing tasks

A pharmacist may delegate the administrative and technical tasks of performing a test for the listed conditions to a registered pharmacy technician or student pharmacist acting under the supervision of the pharmacist.

Reimbursement nondiscrimination note (awareness-level)

The Act states testing/screening/treatment ordered under this paragraph shall not be denied reimbursement under health benefit plans within the pharmacist’s license scope and shall be covered as if performed by a physician/APRN/PA, and bars certain PBM/carrier discrimination against pharmacists acting within scope. Jurisprudence exams rarely grade fee schedules; they do test that these services are within licensed pharmacist practice when statutory conditions are met.

Recordkeeping, Notification & Referral Duties

Across administration and test-and-treat, Illinois repeatedly requires:

1. Appropriate record retention of the service
2. Notification to the patient’s physician/primary provider when the statute says so (“if any” appears in the test-and-treat notification clause—still notify when a physician is identified)
3. Referral when clinically indicated (e.g., reactive HIV testing under PrEP/PEP pathways in 43.5; pediatric well-child referrals in vaccine rules; emergency care after severe reactions)
4. Compliance with VAERS/adverse-event reporting for vaccines
5. I-CARE or PCP within 30 days for vaccine administration under Part 1330.50
6. Hospital settings: follow P&T documentation systems when that pathway is used

Therapy management documentation (connect to 8.1)

When the service is MTM under a standing order, remember retail MTM’s ≤48-hour communication to prescribers for documented services. Test-and-treat notification language is related in spirit: the physician relationship is not discarded because the pharmacist initiated a protocol service.

Personnel Participation Matrix (Administration & Testing)

Integrated Exam Scenarios

Scenario A — Strep test-and-treat. Adult with pharyngitis symptoms; pharmacist uses CLIA-waived Group A strep test and treats under 3(d)(17) with documentation and physician notification. Within statutory list.

Scenario B — Invented disease. Pharmacist claims authority to independently test-and-treat hypertension, diabetes, and depression under the same paragraph without additional protocols. Not supported by the listed 3(d)(17) conditions (those chronic diseases are not on the statutory POC list).

Scenario C — Tech runs the clinic. Tech performs CLIA-waived flu test and independently decides treatment and counseling while pharmacist is off-site. Technical task delegation requires pharmacist supervision; independent clinical management fails.

Scenario D — LAI antipsychotic. Patient presents with valid prescription from treating psychiatrist/APRN/PA; pharmacist completed ACPE training for LAI administration and notifies the prescriber/retains records. Fits 3(d)(4)(D) framework.

Scenario E — Education administration. Pharmacist demonstrates/administers in teaching proper inhaler or injection technique as contemplated by 3(d)(4)(A). Distinguish from unauthorized administration of unrelated injectables without Rx/protocol.

Common Traps

• Expanding test-and-treat beyond the listed conditions (plus true statewide emergency conditions)
• Forgetting CLIA-waived or statewide protocol as the testing tools
• Allowing techs to own clinical treatment decisions
• Skipping physician notification/record retention
• Confusing vaccine standing-order rules with LAI mental health/SUD prescription requirements
• Assuming federal CLIA certificate details replace Illinois scope limits

Chapter 8 Synthesis

Master the matrix of who / what / under what order / with what records. That is how Illinois advanced-practice items convert from anxiety into statute-driven answers. Next chapters return to counseling, DUR, and patient safety—the everyday duties that still apply when clinical services expand.